Best Cardiac and Vascular Disorders Companies in Sweden
The 40 best Cardiac and Vascular Disorders companies in Sweden in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cereno Scientific.
Ranked: Best Cardiac and Vascular Disorders companies in Sweden
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Adolesco A Mobile 3D Gamma Camera for cardiac perfusion imaging. | — | — | — | Kent Berg MD | — | Deadpooled | 6 patents Mobile X‑ray imaging systems with precise detector positioning for medical diagnostics | — |
| 2 | Alder Therapeutics Developer of pluripotent cell therapy treatment for retinal and cardiac diseases | — | — | 4 | Stijn Heessen Co-founder | WebflowMicrosoft Advertisingcore-js+12 | Funding Raised | — | — |
| 3 | Annexin Pharmaceuticals Swedish, public, early-stage biopharma company specialized in vascular diseases | — | — | 5 | — | WordPressMySQLPHP+9 | Public | 89 patents Ocular anti‑VEGF combination therapy using annexin A5 for macular edema and retinal vein occlusion | — |
| 4 | Aptahem Developer of RNA-aptamers to treat thrombotic diseases | — | — | 10 | — | WordPressMySQLPHP+13 | Funding Raised | 19 patents Therapeutic nucleic acid agents for anti‑inflammatory, anticoagulant and organ‑protective applications. | 1 partnership |
| 5 | Calprotect Developer of therapeutics for inflammatory diseases | — | — | — | Alexandru Schiopu Founder & CEO | — | Unfunded | 2 patents Cardiac anti-inflammatory compounds for acute myocardial inflammation treatment | — |
| 6 | Cardiolex Provider of ECG and ECG management system | — | — | 19 | Johanna Genberg CEO | — | Unfunded | — | — |
| 7 | Cardiolex (Acquired 2015) Developer and marketer of electrocardiogram (ECG) systems designed to support and ease the work process. | — | — | 3 | — | — | Acquired | — | — |
| 8 | coala life Developed a digital service where a small wireless heart monitor reading of the heart's ECG and heart sounds | — | — | 29 | — | — | Public | 32 patents Wearable cardiac monitoring: fasteners and electrode assemblies for portable ECG/PCG sensors | — |
Top 12 Cardiac and Vascular Disorders companies in Sweden
#1
Public · Askim, Vastra Gotaland · founded 2012$31.6Mraised▾
Developer of therapeutics for cardiovascular diseases. It offers a lead candidate CS a well-tolerated oral therapy for pulmonary arterial hypertension, CS014 for idiopathic pulmonary fibrosis, and CS585 an oral, highly potent and selective prostacyclin receptor agonist for pulmonary hypertension.
- Nov 2025Post IPO$31.6M
#2
Series A · Sweden · founded 2017 · 11 employees$17.5Mraised▾
Developer of drugs for heart failure treatment. The company has developed an intravenous endogenous peptide hormone that improves cardiac contractility and clinical outcomes in heart failure.
- Jan 2025Series A$19M
- Sep 2022Series A$13.9M
- Feb 2022Series A$3.6M
- Jun 2021Seed—
#3
Funding Raised · Vasteras, Vastmanland County · founded 2007 · 11 employees$4.5Mraised▾
Developer of artificial heart for heart failure patients. It has developed an artificial heart that monitors the function of a natural heart. The patented solution at Realheart TAH is designed to mimic the blood flow pattern and function of the natural human heart that helps patients diagnosed with heart failure.
- Dec 2023Grant (prize money)$832.3K
- Jul 2023Grant (prize money)$78.5K
- May 2023Grant (prize money)—
- Oct 2022Conventional Debt$676.3K
#4
Seed · Malmo, Skane County · founded 2018 · 13 employees$150.7Kraised▾
Provider of wearable AI-based heart health monitoring device. The copay has developed a device that is connected to an app for faster diagnosis and sharing of results with doctors. The device learns the person's heartbeat and notices if there is any deviation in the heartbeat pattern.
- Sep 2024Seed$150.7K
#5
Funding Raised · Lund, Skane County · founded 2012$2.8Mraised▾
Syntach is a provider of a cardiac support device for cardiac health. It has developed a device Syntach CS that restores impaired movement of the mitral valve and supports the heart naturally. It is a permanent, active implant that can be inserted with a minimally invasive technique. It is smaller than existing LVAD devices and suitable for both men and women, as well as people of a smaller build. Features include minimally invasive, long durability, wireless communication, small device, and others.
- Jan 2023Grant (prize money)—
- Dec 2021Grant (prize money)$2.8M
- Grant (prize money)—
#6
Seed · Malmo, Skane County · founded 2017 · 8 employees$2.5Mraised▾
Developer of therapeutics for type-2 diabetes and other diseases. The company has identified and patented small molecules for restoring T2D patient beta-cell function by inhibition of dysfunctional VDAC1. Also, it has shown an effect on mitochondrial diseases like cardiovascular diseases and dementia.
- Mar 2021Seed$2.5M
- Jul 2019Grant (prize money)—
#7
Late Stage · Solna, Stockholm County · founded 2005 · 5 employees$3.4Mraised▾
Attgeno has developed a drug that is administered intravenously for the treatment of acute high blood pressure in the arteries of the lungs for treating blood clots, blood poisoning, or other serious infections. lungs. The company has developed Supernitro, a drug used to release nitric oxide to selectively widen the blood vessels in the lungs administered via the blood vessels to the heart and lungs.
- May 2018PE$3.4M
#8
Acquired · Lund, Skane County · founded 2003$3.6Mraised▾
Chest compression device for sudden cardiac arrest. The device LUCAS has contributed to increasing awareness of the importance of chest compressions as part of resuscitation efforts, allowing for safe CPR during patient transportation.
- Apr 2003Series A$3.6M
#9
Deadpooled · Stockholm, Stockholm County · founded 2002 · 4 employees$2.8Mraised▾
Athera is focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (CVD). Based on the research made at Karolinska Institutet, it is developing its lead product candidate which is the fully human antibody PC-mAb is currently in clinical development. In addition, it has developed a biomarker and companion diagnostic CVDefine kit which is linked to increased risk for cardiovascular disease and could be used for the identification of patients that benefit from the Athera's drugs.
- Dec 2015Series A$2.8M
- Jun 2013PE—
#10
Funding Raised · Lund, Skane County · founded 2004$941.5Kraised▾
Novosense develops low-cost ECG solutions with disposable units. Its CardioSenseSystem line of products consists of components that enables wireless measurement of ECG. Components include CardioPatch which is a disposable sensor applied to the body that contains electrodes, ECG amplifier, radiotransmitter and an ID, and the CardioBase for receiving and analyzing the signals. The sensors can be applied to the body using self-adhesive patches and the data is wirelessly transmitted to CardioBase for further analysis.
- Jan 2019Grant (prize money)$941.5K
#11
Deadpooled · Gothenburg, Vastra Gotaland County · founded 2005$291.5Kraised▾
NovaHep is a biotechnology company that is developing stem cell technology for generating human tissues that can be used in reconstructive surgery or for toxicity and biocompatibility studies. The main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company first 'decellularizes' donated tissue, and then reseeds it with patient autologous stem cells, thus reducing the chance of immune rejection.
- Nov 2016Grant (prize money)$291.5K
#12
Funding Raised · Uppsala, Uppsala County · founded 2015 · 7 employees$110.5Kraised▾
Developer of a healthcare device intended to help diagnose cardiovascular diseases. The company's device has a simple and robust design that is based on a unique position of a pressure sensor and resistance to hydrostatic error and can be used for assessing the severity of narrowings in the coronary arteries and myocardial disease, enabling patients, cardiologists, and healthcare providers to get access to long-lasting benefits.
- Jan 2020Grant (prize money)$55.1K
- Aug 2019Grant (prize money)$55.4K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.